Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children.

PubWeight™: 7.58‹?› | Rank: Top 0.1%

🔗 View Article (PMID 7031583)

Published in Pediatrics on November 01, 1981


C L Cody, L J Baraff, J D Cherry, S M Marcy, C R Manclark

Articles citing this

Tn5-induced mutations affecting virulence factors of Bordetella pertussis. Infect Immun (1983) 8.49

Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev (2005) 6.02

Indications and contraindications for vaccines used in the Expanded Programme on Immunization. Bull World Health Organ (1984) 1.99

Serological response to filamentous hemagglutinin and lymphocytosis-promoting toxin of Bordetella pertussis. Infect Immun (1983) 1.77

Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis. J Exp Med (1990) 1.67

Pyrexia after diphtheria/tetanus/pertussis and diphtheria/tetanus vaccines. Arch Dis Child (1983) 1.52

Human T cell clones define S1 subunit as the most immunogenic moiety of pertussis toxin and determine its epitope map. J Exp Med (1989) 1.49

Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough. Infect Immun (1990) 1.44

Rate of recurrent collapse after vaccination with whole cell pertussis vaccine: follow up study. BMJ (1998) 1.40

The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health (1995) 1.36

Immune response to the B oligomer of pertussis toxin. Infect Immun (1987) 1.36

Reactogenicity of fluid compared with adsorbed diphtheria-pertussis-tetanus vaccine. Can Med Assoc J (1984) 1.33

Pertussis toxin is required for pertussis vaccine encephalopathy. Proc Natl Acad Sci U S A (1985) 1.31

Pertussis toxin analog with reduced enzymatic and biological activities is a protective immunogen. Infect Immun (1990) 1.19

Failure to vaccinate against whooping cough. Arch Dis Child (1986) 1.18

Pertussis: the disease and new diagnostic methods. Clin Microbiol Rev (1988) 1.16

ABC of 1 to 7: whooping cough. Br Med J (Clin Res Ed) (1982) 1.14

Diphtheria-tetanus-pertussis immunization and sudden infant death syndrome. Am J Public Health (1987) 1.09

Mechanism of pertussis toxin B oligomer-mediated protection against Bordetella pertussis respiratory infection. Infect Immun (1990) 1.08

Skin rash after triple vaccine. Arch Dis Child (1987) 1.07

Pertussis: Microbiology, Disease, Treatment, and Prevention. Clin Microbiol Rev (2016) 1.07

Adverse reactions to the preschool (fifth) dose of adsorbed diphtheria-pertussis-tetanus vaccine in Canadian children. CMAJ (1991) 1.04

Pertussis holotoxoid formed in vitro with a genetically deactivated S1 subunit. Proc Natl Acad Sci U S A (1989) 1.03

Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein. Infect Immun (1994) 1.02

MHC-restricted recognition of immunogenic T cell epitopes of pertussis toxin reveals determinants in man distinct from the ADP-ribosylase active site. J Exp Med (1988) 0.96

Development of a rat model for respiratory infection with Bordetella pertussis. Infect Immun (1989) 0.96

Pertussis vaccine: myths and realities. Can Fam Physician (1988) 0.95

Whooping cough and pertussis vaccine. Br Med J (Clin Res Ed) (1983) 0.92

Pertussis vaccine and encephalopathy after the Loveday trial. CMAJ (1988) 0.89

A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers. Hum Vaccin Immunother (2012) 0.86

Humoral and cellular immune responses in mice immunized with recombinant Mycobacterium bovis Bacillus Calmette-Guérin producing a pertussis toxin-tetanus toxin hybrid protein. Infect Immun (1999) 0.85

Feasibility study for identifying adverse events attributable to vaccination by record linkage. Epidemiol Infect (1995) 0.85

Role of endotoxin in alterations of hepatic drug metabolism by diphtheria and tetanus toxoids and pertussis vaccine adsorbed. Infect Immun (1992) 0.85

Design and development of stable, water-soluble, human Toll-like receptor 2 specific monoacyl lipopeptides as candidate vaccine adjuvants. J Med Chem (2013) 0.84

Licensed pertussis vaccines in the United States. History and current state. Hum Vaccin Immunother (2014) 0.84

Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid? CMAJ (1993) 0.83

Bordetella pertussis adenylate cyclase: isolation and purification by calmodulin-sepharose 4B chromatography. Infect Immun (1987) 0.83

Toxicity of pertussis vaccine. Br Med J (Clin Res Ed) (1982) 0.83

Local adverse reactions to diphtheria and tetanus toxoids and pertussis vaccine, adsorbed, in Surrey, BC. CMAJ (1989) 0.82

Evaluation of the mouse model for study of encephalopathy in pertussis vaccine recipients. Infect Immun (1989) 0.82

Frequent symptoms after DTPP vaccinations. Arch Dis Child (1991) 0.80

Progress towards a new pertussis vaccine. Br Med J (Clin Res Ed) (1986) 0.80

Myocarditis after triple immunisation. Arch Dis Child (1986) 0.80

Active immunization in the United States: developments over the past decade. Clin Microbiol Rev (2001) 0.80

Th1 versus Th2 T cell polarization by whole-cell and acellular childhood pertussis vaccines persists upon re-immunization in adolescence and adulthood. Cell Immunol (2016) 0.79

Detection of antibodies inhibiting the ADP-ribosyltransferase activity of pertussis toxin in human serum. J Clin Microbiol (1992) 0.79

Monoclonal antibodies that inhibit ADP-ribosyltransferase but not NAD-glycohydrolase activity of pertussis toxin. Infect Immun (1990) 0.78

Pertussis toxin-induced alterations of murine hepatic drug metabolism following administration of diphtheria and tetanus toxoids and pertussis vaccine adsorbed. Infect Immun (1993) 0.77

Pertussis and pertussis vaccine. Can Med Assoc J (1985) 0.77

A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model. Clin Vaccine Immunol (2010) 0.77

Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany. Eur J Pediatr (1998) 0.76

Pertussis: should we immunise neurologically disabled and developmentally delayed children? Br Med J (Clin Res Ed) (1983) 0.75

The United States--The Netherlands Round Table Conference on immunization. Summary report. Public Health Rep (1983) 0.75

Neurology-important advances in clinical medicine: neurologic complications of routine immunization. West J Med (1982) 0.75

Highlights of the 11th International Bordetella Symposium: from Basic Biology to Vaccine Development. Clin Vaccine Immunol (2016) 0.75

Adverse events temporally associated with immunizing agents: 1987 report. CMAJ (1989) 0.75

Adverse events following primary and secondary immunisation with whole-cell pertussis: a systematic review protocol. BMJ Open (2017) 0.75

Diphtheria-tetanus overimmunization in children with no records: can it be prevented? CMAJ (1989) 0.75

Strategies and new developments to control pertussis, an actual health problem. Pathog Dis (2015) 0.75

No Crying Episode after DwPT- A Case of Congenital Hypothyroidism. J Clin Diagn Res (2013) 0.75

Statement on pertussis immunization. National Advisory Committee on Immunization. CMAJ (1993) 0.75

Acellular versus whole-cell pertussis vaccines. Can J Infect Dis (1992) 0.75

Role of whole-cell pertussis vaccine in severe local reactions to the preschool (fifth) dose of diphtheria-pertussis-tetanus vaccine. CMAJ (1994) 0.75

Survey to establish the incidence of minor side effects in infants following protective immunization. J R Coll Gen Pract (1989) 0.75

Pertussis: the disease and the vaccine. Can Fam Physician (1986) 0.75

Immunization of children in Calgary. Can Med Assoc J (1984) 0.75

Monokine production following in vitro stimulation of the THP-1 human monocytic cell line with pertussis vaccine components. J Clin Immunol (1998) 0.75

Articles by these authors

Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control. N Engl J Med (1996) 4.71

Extracytoplasmic adenylate cyclase of Bordetella pertussis. Proc Natl Acad Sci U S A (1976) 3.57

Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase. J Biol Chem (1983) 3.31

Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N Engl J Med (1983) 2.91

Does influenza vaccination prevent asthma exacerbations in children? J Pediatr (2001) 2.89

Separation and purification of the hemagglutinins from Bordetella pertussis. Infect Immun (1983) 2.85

Implementation of clinical guidelines using a computer charting system. Effect on the initial care of health care workers exposed to body fluids. JAMA (1997) 2.83

Role of antibody to leukocytosis-promoting factor hemagglutinin and to filamentous hemagglutinin in immunity to pertussis. Infect Immun (1981) 2.77

Identification of a 69-kilodalton nonfimbrial protein as an agglutinogen of Bordetella pertussis. Infect Immun (1988) 2.55

Large-quantity production of chicken embryo tracheal organ cultures and use in virus and mycoplasma studies. Appl Microbiol (1970) 2.54

Elevated cord macroglobulins in the diagnosis of intrauterine infections. N Engl J Med (1966) 2.50

ADP-ribosylation of transducin by pertussis toxin blocks the light-stimulated hydrolysis of GTP and cGMP in retinal photoreceptors. J Biol Chem (1984) 2.39

Haemophilus influenzae meningitis. A national study of secondary spread in household contacts. N Engl J Med (1979) 2.34

Aerosol infection of mice with Bordetella pertussis. Infect Immun (1980) 2.31

Epidemic measles in young adults. Clinical, epidemiologic, and serologic studies. Ann Intern Med (1979) 2.29

Pertussis in adults. Ann Intern Med (1998) 2.25

Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics (1997) 2.25

Urban measles in the vaccine era: a clinical, epidemiologic, and serologic study. J Pediatr (1972) 2.24

Phase-shift markers in Bordetella: alterations in envelope proteins. J Infect Dis (1981) 2.23

Sales of nonprescription cold remedies: a unique method of influenza surveillance. Pediatr Res (1979) 2.22

Bacterial meningitis and septicemia in sickle cell disease. Am J Dis Child (1977) 2.19

Filamentous hemagglutinin has a major role in mediating adherence of Bordetella pertussis to human WiDr cells. Infect Immun (1986) 2.18

DTP-associated reactions: an analysis by injection site, manufacturer, prior reactions, and dose. Pediatrics (1984) 2.15

Pulse oximetry as a fifth pediatric vital sign. Pediatrics (1997) 2.11

The 'new' epidemiology of measles and rubella. Hosp Pract (1980) 2.07

Protective activities of the filamentous hemagglutinin and the lymphocytosis-promoting factor of Bordetella pertussis in mice. J Infect Dis (1984) 1.96

Sensitivity and specificity of clinical case definitions for pertussis. Am J Public Health (1988) 1.93

Comparison of type 2 and type 6 fimbriae of Bordetella pertussis by using agglutinating monoclonal antibodies. Infect Immun (1988) 1.92

Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis. Pediatr Infect Dis J (1994) 1.90

Efficacy of cervical spine immobilization methods. J Trauma (1983) 1.89

Why do physicians prescribe antibiotics for children with upper respiratory tract infections? JAMA (1998) 1.89

Lectin-like binding of pertussis toxin to a 165-kilodalton Chinese hamster ovary cell glycoprotein. J Biol Chem (1988) 1.88

Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. Clin Infect Dis (2000) 1.85

The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med (2001) 1.84

A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics (1998) 1.84

A search for Bordetella pertussis infection in university students. Clin Infect Dis (1992) 1.83

Intracellular localization of the dermonecrotic toxin of Bordetella pertussis. Infect Immun (1979) 1.83

The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United States: a comparative study. Curr Probl Pediatr (1984) 1.81

Serological response to filamentous hemagglutinin and lymphocytosis-promoting toxin of Bordetella pertussis. Infect Immun (1983) 1.77

Agglutinating monoclonal antibodies that specifically recognize lipooligosaccharide A of Bordetella pertussis. Infect Immun (1988) 1.71

Immunologic response to early and routine DTP immunization in infants. Pediatrics (1984) 1.71

Binding of pertussis toxin to eucaryotic cells and glycoproteins. Infect Immun (1989) 1.71

Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics (2001) 1.70

Pertussis in German adults. Clin Infect Dis (1995) 1.68

Evidence assessment of management of acute otitis media: II. Research gaps and priorities for future research. Pediatrics (2001) 1.67

Pertussis toxin substrate, the putative Ni component of adenylyl cyclases, is an alpha beta heterodimer regulated by guanine nucleotide and magnesium. Proc Natl Acad Sci U S A (1983) 1.67

Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis. J Exp Med (1990) 1.67

Infants and children with convulsions and hypotonic-hyporesponsive episodes following diphtheria-tetanus-pertussis immunization: follow-up evaluation. Pediatrics (1988) 1.66

Ns and Ni, the stimulatory and inhibitory regulatory components of adenylyl cyclases. Purification of the human erythrocyte proteins without the use of activating regulatory ligands. J Biol Chem (1984) 1.62

Frequency of unrecognized Bordetella pertussis infections in adults. Clin Infect Dis (1995) 1.59

Stimulation and inhibition of adenylyl cyclases mediated by distinct regulatory proteins. Nature (1983) 1.59

Admission decisions in emergency department chest pain patients at low risk for myocardial infarction: patient versus physician preferences. Ann Emerg Med (1996) 1.58

Nonfermentative bacilli associated with man. I. Nomenclature. Am J Clin Pathol (1970) 1.57

'Pertussis vaccine encephalopathy': it is time to recognize it as the myth that it is. JAMA (1990) 1.55

Bacterial-viral interrelations in respiratory infections of children. N Engl J Med (1967) 1.53

Role of the A subunit of pertussis toxin in alteration of Chinese hamster ovary cell morphology. Infect Immun (1987) 1.52

A comparison of pulse oximetry and respiratory rate in patient screening. Respir Med (1996) 1.51

The risk of Guillain-Barré syndrome after tetanus-toxoid-containing vaccines in adults and children in the United States. Am J Public Health (1997) 1.50

HL-A antigens and antibody response after influenza A vaccination. Decreased response associated with HL-A type W16. N Engl J Med (1976) 1.49

Identification of Bordetella pertussis infection by shared-primer PCR. J Clin Microbiol (1994) 1.49

Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying. Pediatrics (1993) 1.49

Birth weight and genital mycoplasmas in pregnancy. N Engl J Med (1971) 1.48

Purification and characterization of fimbriae isolated from Bordetella pertussis. Infect Immun (1985) 1.47

Lack of significant person-to-person spread of swine influenza-like virus following fatal infection in an immunocompromised child. Am J Epidemiol (1984) 1.47

Incorporating patient preferences into practice guidelines: management of children with fever without source. Ann Emerg Med (1994) 1.44

Erythema migrans after ceftriaxone treatment of aseptic meningitis caused by Borrelia burgdorferi. Pediatr Infect Dis J (2001) 1.43

Monoclonal antibodies to pertussis toxin: utilization as probes of toxin function. Hybridoma (1989) 1.43

The role of antibiotics, immunizations, and adenoviruses in pertussis. Pediatrics (1978) 1.42

Acute fever and petechial rash associated with influenza A virus infection. Clin Infect Dis (1999) 1.41

Capillary refill--is it a useful predictor of hypovolemic states? Ann Emerg Med (1991) 1.41

Mycoplasma pneumoniae infections and exanthems. J Pediatr (1975) 1.39

Care of the febrile child: an annotated bibliography. Am J Emerg Med (1991) 1.38

A comparison of laboratory and clinical methods for diagnosing pertussis in an outbreak in a facility for the developmentally disabled. J Infect Dis (1988) 1.37

Structural characterization of pertussis toxin A subunit. J Biol Chem (1987) 1.36

Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics (2003) 1.36

Immune response to the B oligomer of pertussis toxin. Infect Immun (1987) 1.36

Household contact study of Bordetella pertussis infections. Clin Infect Dis (1995) 1.35

The evaluation of racemic epinephrine in the treatment of infectious croup. Pediatrics (1973) 1.33

Epitopes on the S1 subunit of pertussis toxin recognized by monoclonal antibodies. Infect Immun (1989) 1.32

Improved method for collection of nasal mucus. J Infect Dis (1977) 1.31

Hemorrhage from cecal ulcers of cytomegalovirus infection: report of a case. Ann Surg (1973) 1.30

Bordetella pertussis infections and sudden unexpected deaths in children. Eur J Pediatr (1996) 1.29

Therapy of Haemophilus influenzae meningitis reconsidered. N Engl J Med (1972) 1.27

Pertussis caused by an erythromycin-resistant strain of Bordetella pertussis. Pediatr Infect Dis J (1995) 1.26

International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19-20 July 2007. Vaccine (2008) 1.25

Pertussis encephalopathy with a normal brain biopsy and elevated lymphocytosis-promoting factor antibodies. Pediatr Infect Dis (1984) 1.25

Pertussis toxin inhibition of chemotaxis and the ADP-ribosylation of a membrane protein in a human-mouse hybrid cell line. Proc Natl Acad Sci U S A (1985) 1.24

A prospective search for congenital dermal abnormalities of the craniospinal axis. J Pediatr (1975) 1.23

Possible temporal association between diphtheria-tetanus toxoid-pertussis vaccination and sudden infant death syndrome. Pediatr Infect Dis (1983) 1.23

The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ (2000) 1.23

Failure of cefamandole in treatment of meningitis due to Haemophilus influenzae type b. J Infect Dis (1978) 1.22

Advance directives. Effect of type of directive on physicians' therapeutic decisions. Arch Intern Med (1993) 1.22

Measles revaccination. Persistence and degree of antibody titer by type of immune response. Am J Dis Child (1978) 1.22